Oncolytics Biotech
@Oncolytics
Followers
3K
Following
82
Media
517
Statuses
2K
Oncolytics is developing pelareorep, an IV delivered I-O agent, which introduces double-stranded RNA into cancer cells. Contact company: https://t.co/sNAsxxiOi5
Calgary, Alberta
Joined March 2009
Today we held our AGM, reported Q2 2025 financial results, reiterated our plan to pursue a registration-enabling study in first-line mPDAC and committed to limiting dilutive financings by terminating our ATM and ELOC. Read more: $ONCY
0
0
3
On Friday, August 8, at 10 a.m. ET, we will hold our virtual-only AGM for shareholders. Following the meeting, our CEO, Jared Kelly, will provide a corporate update. Our Q2 2025 financial results will also be reported that morning. Learn more: $ONCY
0
2
5
The most fun image & video creation tool in the world is here. Try it for free in the Grok App.
0
57
502
We have initiated regulatory discussions with the U.S. FDA for a registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma. Read more in our press release: . #PancreaticCancer #PDAC #CancerResearch $ONCY
0
2
8
This recent @TargetedOnc feature highlights survival data for our investigational immunotherapy #pelareorep and its potential in hard-to-treat cancers. The data support advancement of pelareorep into registration-enabling studies. Read the full article:
targetedonc.com
Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits in hard-to-treat cancers.
0
4
7
Thank you to the KOLs who joined our event to discuss the robust data supporting the clinical advancement of our investigational immunotherapy, #pelareorep, into registration-enabling studies. If you missed the live event, watch the replay here:
0
3
5
Translational data for our investigational immunotherapy, #pelareorep, show viral replication and immune activation across multiple cancers. These findings reinforce its mechanism of action and potential as a platform therapy. Read our press release:
0
3
7
On July 22 we will host a KOL event on the potential of our investigational #immunotherapy, #pelareorep, in pancreatic and gastrointestinal cancers. Experts will discuss our clinical data and how pelareorep fits into the treatment landscape. Register:
1
4
9
Today we highlighted data from our completed clinical trials. Our investigational oncolytic virus immunotherapy, #pelareorep, showed strong survival benefits in pancreatic and breast cancers, supporting advancement to registration-enabling studies. More:
0
0
3
Andrew Aromando has joined Oncolytics as Chief Business Officer. He will lead global business development while contributing to corporate, clinical and regulatory strategies as we pursue aggressive clinical and business development initiatives. Read more:
0
0
6
This article by @LetsWinPC highlights #PancreaticCancer research that was presented at #ASCO25, including the new data we shared showing how our investigational therapy #pelareorep stimulates the immune system and primes tumors for treatment. Read more:
letswinpc.org
The 2025 ASCO meeting featured pancreatic cancer research including a new treatment modality and a new treatment combination.
0
3
3
This week, our CMO, Dr. Thomas Heineman, MD, PhD, will speak as part of Technology Networks’ virtual event on the advances in #immunooncology. Register here to learn how #pelareorep is driving progress in cancers by activating the immune system:
0
2
6
Today we announced that Jared Kelly has been named CEO of Oncolytics. With expertise in biotech dealmaking and corporate strategy, his leadership will be critical as we advance #pelareorep as a potential new #immunotherapy for #cancer. Read more:
1
1
7
We shared new data from the GOBLET study in collaboration with @AIO_Onkologie at #ASCO2025 showing how our candidate, #pelareorep, in combo with chemotherapy and a checkpoint inhibitor, activates immune responses in #PancreaticCancer patients:
0
1
4
We are headed to #BIO2025! Join our VP of Business Development, Christophe Degois, as he highlights how Oncolytics is partnering to transform #ImmunoOncology. Schedule a meeting with Christophe: @IAmBiotech
0
1
6
New data from the GOBLET #ClinicalTrial presented with @AIO_Onkologie at #ASCO25 demonstrate how our investigational treatment #pelareorep, in combination with chemotherapy & a checkpoint inhibitor, activates immune responses in patients with #PDAC:
0
0
1
We are looking forward to connecting with peers in the #oncology community at #ASCO25 as we share new data showing how our investigational #immunotherapy #pelareorep activates immune responses in #PancreaticCancer. Poster details here:
0
0
2
Today, we shared Q1 2025 financial results and highlighted recent clinical momentum. 💡 Shared data at #ASCOGI. 💡 #Pelareorep discussed by KOLs during an event hosted by H.C. Wainwright. 💡 Poster to be presented at #ASCO25. Read more: $ONCY
0
0
1
Join us on May 14 at 4:30 p.m. ET as we host a conference call and webcast to discuss our first quarter 2025 financial results and recent operational highlights. Read more and access the link here:
0
0
1
Over the weekend, our team joined with our collaborators from @PanCAN for #PanCANPurpleStride San Diego, the ultimate walk to end #PancreaticCancer. Learn how you can join us in advancing research and honoring those impacted by pancreatic cancer:
1
3
5
New data showing #pelareorep’s ability to activate immune responses in patients with #PancreaticCancer will be presented at #ASCO25. Learn more here: #CancerResearch #ImmunoOncology #Oncology
0
3
6